Acibadem City Clinic Tokuda Hospital is the largest medical facility in Bulgaria, built and developed with private investments. It was opened in 2006 as part of a Japanese medical group, owned by the physician and entrepreneur Dr. Torao Tokuda.

During the past decade, MHAT 'Tokuda Hospital Sofia', EAD conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 12 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT 'Tokuda Hospital Sofia', EAD" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Celgene" with 2 trials sponsored, "Can-Fite BioPharma" with 1 trials sponsored and "Daiichi Sankyo, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT 'Tokuda Hospital Sofia', EAD" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator and "Norgine" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "MHAT 'Tokuda Hospital Sofia', EAD" are "Hepatitis B, Chronic" (3 trials), "Ulcerative Colitis" (2 trials), "Breast Cancer" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Chronic Kidney Disease" (1 trials). Many other conditions were trialed in "MHAT 'Tokuda Hospital Sofia', EAD" in a lesser frequency.

Most popular intervention types in "MHAT 'Tokuda Hospital Sofia', EAD" are "Drug" (11 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "RPC1063" (2 trials), "1.25 g PA21 (250 mg iron)" (1 trials), "10.0 g PA21 (2,000 mg iron)" (1 trials) and "12.5 g PA21 (2,500 mg iron)" (1 trials). Other intervention names were less common.

The vast majority of trials in "MHAT 'Tokuda Hospital Sofia', EAD" are 16 trials for "All" genders.

Currently, there are NaN active trials in "MHAT 'Tokuda Hospital Sofia', EAD". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in MHAT 'Tokuda Hospital Sofia', EAD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MHAT 'Tokuda Hospital Sofia', EAD, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".